Notch4 is a transmembrane receptor belonging to the Notch family, which plays a critical role in cell-cell communication, regulating processes like cell differentiation, proliferation, and apoptosis. The Notch signaling pathway is evolutionarily conserved and involves ligand-receptor interactions that trigger proteolytic cleavage of the receptor, releasing the intracellular domain (NICD) to regulate target gene expression. Notch4 is primarily expressed in vascular endothelial cells and is implicated in angiogenesis, vascular remodeling, and maintaining vascular integrity. Dysregulation of Notch4 has been linked to developmental disorders, inflammatory diseases, and cancers, including breast cancer and glioblastoma.
NOTCH4 antibodies are essential tools for detecting and studying the expression, localization, and function of the Notch4 protein. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Researchers utilize them to investigate Notch4’s role in signaling pathways, its interaction with ligands (e.g., Jagged, Delta-like), and its pathological contributions. Some studies focus on Notch4’s extracellular domain (ECD) or intracellular domain (ICD) to explore receptor activation or downstream signaling.
Therapeutic interest in Notch4 has grown due to its association with tumor angiogenesis and resistance to chemotherapy. NOTCH4 antibodies also aid in validating experimental models (e.g., knockout mice) and assessing potential biomarkers or drug targets. However, challenges remain in specificity and cross-reactivity with other Notch family members, emphasizing the need for well-validated antibodies in research and clinical applications.